Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13D/A

Vir Biotechnology, Inc.

VIRNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 6, 2026Accepted Nov 6, 2026, 6:55 PM ESTFiling CIK 1706431Accession 0001012975-26-001020
Share

Structured filing — SCHEDULE 13D/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
Vir Biotechnology, Inc.
Company CIK
0001706431
Street
1800 Owens Street, Suite 900
City
San Francisco
State / country code
CA
Postal code
94158

Statement details

Amendment number
8
Security class
Common Stock, $0.0001 par value
Event date
11/04/2026
Previously filed indication
false

Authorized notification person 1

Name
Mark McDonnell
Phone
(773) 380-6600
Street
ARCH Venture Management, LLC
Street (continued)
8755 W. Higgins Road, Suite 1025
City
Chicago
State / country code
IL
Postal code
60631

Reporting person 1

Name
ARCH Venture Fund IX, L.P.
Reporting person CIK
0001666306
No reporting person CIK indication
N
Citizenship / organization
DE
Reporting person type
PN
Source of funds code
WC
Legal proceedings indication
N
Aggregate amount owned
11,897,988
Percent of class
6.9
Sole voting power
0
Shared voting power
11,897,988
Sole dispositive power
0
Shared dispositive power
11,897,988
Aggregate excludes certain shares
N

Reporting person 2

Name
ARCH Venture Fund IX Overage, L.P.
Reporting person CIK
0001666307
No reporting person CIK indication
N
Citizenship / organization
DE
Reporting person type
PN
Source of funds code
WC
Legal proceedings indication
N
Aggregate amount owned
11,897,988
Percent of class
6.9
Sole voting power
0
Shared voting power
11,897,988
Sole dispositive power
0
Shared dispositive power
11,897,988
Aggregate excludes certain shares
N

Reporting person 3

Name
ARCH Venture Partners IX, L.P.
Reporting person CIK
0001723173
No reporting person CIK indication
N
Citizenship / organization
DE
Reporting person type
PN
Source of funds code
AF
Legal proceedings indication
N
Aggregate amount owned
11,897,988
Percent of class
6.9
Sole voting power
0
Shared voting power
11,897,988
Sole dispositive power
0
Shared dispositive power
11,897,988
Aggregate excludes certain shares
N

Reporting person 4

Name
ARCH Venture Partners IX Overage, L.P.
Reporting person CIK
0001723172
No reporting person CIK indication
N
Citizenship / organization
DE
Reporting person type
PN
Source of funds code
WC
Legal proceedings indication
N
Aggregate amount owned
11,897,988
Percent of class
6.9
Sole voting power
0
Shared voting power
11,897,988
Sole dispositive power
0
Shared dispositive power
11,897,988
Aggregate excludes certain shares
N

Reporting person 5

Name
ARCH Venture Partners IX, LLC
Reporting person CIK
0001723174
No reporting person CIK indication
N
Citizenship / organization
DE
Reporting person type
OO
Source of funds code
AF
Legal proceedings indication
N
Aggregate amount owned
11,897,988
Percent of class
6.9
Sole voting power
0
Shared voting power
11,897,988
Sole dispositive power
0
Shared dispositive power
11,897,988
Aggregate excludes certain shares
N

Reporting person 6

Name
Robert Nelsen
Reporting person CIK
0001219042
No reporting person CIK indication
N
Citizenship / organization
X1
Reporting person type
IN
Source of funds code
AF
Legal proceedings indication
N
Aggregate amount owned
12,508,029
Percent of class
7.3
Sole voting power
576,148
Shared voting power
11,931,881
Sole dispositive power
576,148
Shared dispositive power
11,931,881
Aggregate excludes certain shares
N

Reporting person 7

Name
Keith Crandell
Reporting person CIK
0001219039
No reporting person CIK indication
N
Citizenship / organization
X1
Reporting person type
IN
Source of funds code
AF
Legal proceedings indication
N
Aggregate amount owned
12,170,952
Percent of class
7.1
Sole voting power
272,964
Shared voting power
11,897,988
Sole dispositive power
272,964
Shared dispositive power
11,897,988
Aggregate excludes certain shares
N

Reporting person 8

Name
Clinton Bybee
Reporting person CIK
0001219043
No reporting person CIK indication
N
Citizenship / organization
X1
Reporting person type
IN
Source of funds code
AF
Legal proceedings indication
N
Aggregate amount owned
11,989,718
Percent of class
7.0
Sole voting power
30,570
Shared voting power
11,959,148
Sole dispositive power
30,570
Shared dispositive power
11,959,148
Aggregate excludes certain shares
N

Item 1

Issuer

Vir Biotechnology, Inc.

Security title

Common Stock, $0.0001 par value

Principal address

Comment

This Amendment No. 8 (the "Amendment No.8") amends the statement on Schedule 13D filed on November 8, 2019 (as amended, the "Original 13D"), relating to the Common Stock, $0.0001 par value per share (the "Common Stock"), of Vir Biotechnology, Inc. (the "Issuer") having its principal executive office at 1800 Owens Street, Suite 900, San Francisco, California 94158. Certain terms used but not defined in this Amendment No. 8 have the meanings assigned thereto in the Original 13D.

Item 4

Purpose of transaction

Each of AVF IX and AVF IX Overage acquired the Common Stock for investment purposes. Depending on market conditions, the continuing evaluation of the business and prospects of the Issuer and other factors, AVF IX and AVF IX Overage and other Reporting Persons may dispose of or acquire additional shares of Common Stock of the Issuer. From November 3, 2026 to November 5, 2026, AVF IX and AVF IX Overage sold 347,819 shares and 448,356 shares respectively, of Common Stock for cash. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (j) Any action similar to any of those enumerated above.

Item 5

Number of shares

Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets. (ii) shared power to vote or to direct the vote: See line 8 of cover sheets. (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets. (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.

Transactions

Except as set forth in the following, none of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days: On November 3, 2026, AVF IX sold 94,905 shares of Common Stock and AVF IX Overage sold 122,337 shares of Common Stock at a weighted average sale price of $11.24 per share, in multiple transactions at prices ranging from $11.10 to $11.37, inclusive. On November 4, 2026, AVF IX sold 146,562 shares of Common Stock and AVF IX Overage sold 188,926 shares of Common Stock at a weighted average sale price of $11.60 per share, in multiple transactions at prices ranging from $11.17 to $11.81, inclusive. On November 5, 2026, AVF IX sold 99,274 shares of Common Stock and AVF IX Overage sold 127,970 shares of Common Stock at a weighted average sale price of $11.26 per share, in multiple transactions at prices ranging from $10.98 to $11.98, inclusive. On November 5, 2026, AVF IX sold 7,078 shares of Common Stock and AVF IX Overage sold 9,123 shares of Common Stock at a weighted average sale price of $12.06 per share, in multiple transactions at prices ranging from $11.99 to $12.16, inclusive. The reported prices are weighted average prices. The Reporting Persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.

Percentage of class

Items 5(a)-(c) of the Original 13D are hereby amended and supplemented as follows: AVF IX is the record owner of 5,055,689 shares of Common Stock ("AVF IX Record Shares"). AVP IX LP, as the sole general partner of AVF IX, may be deemed to beneficially own the AVF IX Record Shares. AVP IX LLC, as the sole general partner of AVP IX LP, may be deemed to beneficially own the AVF IX Record Shares. AVF IX Overage is the record holder of 6,842,299 shares of Common Stock ("IX Overage Record Shares" and, together with the AVF IX Record Shares, the "Record Shares"). AVP IX Overage GP, as the sole general partner of AVF IX Overage, may be deemed to beneficially own the IX Overage Record Shares. AVP IX LLC, as the sole general partner of AVP IX Overage GP, may be deemed to beneficially own the IX Overage Record Shares. By virtue of their relationship as affiliated entities who have overlapping general partners and managing directors, each entity and Reporting Person may be deemed to share the power to direct the disposition and vote of the Record Shares. In addition, each of the AVP IX Managing Directors may be deemed to share the power to direct the disposition and vote of the Record Shares. Each Reporting Person disclaims beneficial ownership of all securities except for the shares, if any, held of record by such Reporting Person. The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated based on the 171,270,773 shares of Common Stock outstanding as of October 28, 2026 as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 4, 2026. In addition, as of November 6, 2026, Crandell is a record holder of 272,964 Shares of Common Stock, Bybee is a record holder of 30,570 shares of Common Stock, and Nelsen separately holds 576,148 shares of Common Stock. For Nelsen and Bybee, respectively, 33,893 shares and 61,160 shares of Common Stock held by family trusts are included in Shared Voting and Shared Dispositive figures on cover sheets.

Signature comments

* This Amendment No. 8 to the Schedule 13D was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24 to the Form 3 relating to the beneficial ownership of shares of Vir Biotechnology, Inc. by the Reporting Persons filed with the Securities and Exchange Commission on October 10, 2019 and incorporated herein in its entirety by reference.

Signature 1

Reporting person
ARCH Venture Fund IX, L.P.
Signed
ARCH Venture Partners IX, L.P. · ARCH Venture Partners IX, LLC · /s/ Mark McDonnell
Title
its General Partner · its General Partner · Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date
11/06/2026 · 11/06/2026 · 11/06/2026

Signature 2

Reporting person
ARCH Venture Fund IX Overage, L.P.
Signed
ARCH Venture Partners IX Overage, L.P. · ARCH Venture Partners IX, LLC · /s/ Mark McDonnell
Title
its General Partner · its General Partner · Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date
11/06/2026 · 11/06/2026 · 11/06/2026

Signature 3

Reporting person
ARCH Venture Partners IX, L.P.
Signed
ARCH Venture Partners IX, LLC · /s/ Mark McDonnell
Title
its General Partner · Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date
11/06/2026 · 11/06/2026

Signature 4

Reporting person
ARCH Venture Partners IX Overage, L.P.
Signed
ARCH Venture Partners IX, LLC · /s/ Mark McDonnell
Title
its General Partner · Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date
11/06/2026 · 11/06/2026

Signature 5

Reporting person
ARCH Venture Partners IX, LLC
Signed
/s/ Mark McDonnell
Title
Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date
11/06/2026

Signature 6

Reporting person
Robert Nelsen
Signed
/s/ Mark McDonnell
Title
Mark McDonnell as Attorney-in-Fact for Robert Nelsen
Date
11/06/2026

Signature 7

Reporting person
Keith Crandell
Signed
/s/ Mark McDonnell
Title
Mark McDonnell as Attorney-in-Fact for Keith Crandell
Date
11/06/2026

Signature 8

Reporting person
Clinton Bybee
Signed
/s/ Mark McDonnell
Title
Mark McDonnell as Attorney-in-Fact for Clinton Bybee
Date
11/06/2026

Company context

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of oncologic malignancies.

Current securities

Recent company filings

  1. 424B5 filingNov 16, 2026
  2. Entry into a Material Definitive Agreement · Other EventsNov 16, 2026
  3. 424B5 filingNov 16, 2026
  4. 424B5 filingNov 12, 2026
  5. S-3ASR filingNov 12, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.